A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)
| Autor: | Hiroshi Saeki, Hironaga Satake, Yasunori Emi, Eiji Oki, Soichiro Maekawa, Koji Ando, Kenji Sakai, Mototsugu Shimokawa, Masahiro Hamanoue, Yoshihiko Maehara, Yoshito Akagi, Yasuo Sakamoto, Hideo Baba, Toyokuni Suenaga, Takayuki Shimose, Seiichiro Kai |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Male Gastroenterology 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Prospective Studies Glucuronosyltransferase Prospective cohort study Aged 80 and over Leukopenia Hematology General Medicine Middle Aged Anorexia Bevacizumab Treatment Outcome 030220 oncology & carcinogenesis Female Fluorouracil medicine.symptom Colorectal Neoplasms medicine.drug Adult Diarrhea medicine.medical_specialty Neutropenia Irinotecan Disease-Free Survival Capecitabine 03 medical and health sciences Asian People Internal medicine medicine Humans Aged XELIRI business.industry medicine.disease 030104 developmental biology Surgery Camptothecin Neoplasm Recurrence Local business Febrile neutropenia |
| Zdroj: | International journal of clinical oncology. 22(5) |
| ISSN: | 1437-7772 |
| Popis: | This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELIRI (irinotecan 200 mg/m2 on day 1 plus capecitabine 800 mg/m2 b.i.d. on days 1–14) every 3 weeks. The primary endpoint was the objective tumor response rate. A total of 36 patients were enrolled in this study from July 2011 to September 2012. One patient did not fulfill the eligibility criteria and one patient withdrew their consent before the start of the treatment protocol. The confirmed objective response rate was 58.8% (95% CI 35.1–70.2%). The median progression-free survival was 9.6 months (95% CI 5.1–11.1 months) and the median overall survival was 23.1 months (95% CI 11.3–36.7 months). The grade ≥3 adverse events that were frequently encountered in this study were neutropenia (31.4%), leukopenia (22.9%), diarrhea (22.9%), anemia (20.0%), anorexia (20.0%) and febrile neutropenia (17.2%). The frequency of grade 3/4 adverse events, such as neutropenia and leukopenia, was much higher in patients with a UGT1A1 polymorphism. A first-line therapy comprising XELIRI plus bevacizumab yielded a promising response rate. However, careful attention should be given to adverse clinical events in Japanese patients receiving treatment with unresectable or recurrent CRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink